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COST-EFFECTIVENESS OF PROTON PUMP
INHIBITORS IN GASTRIC ULCER
Ikeda S, Ikegami N
Keio University, School of Medicine, Tokyo, japan
Recently, the third proton pump inhibitor (PPI), Ra-
beprazole, has been marketed in Japan. However, its eco-
nomic aspect has not been studied.
OBJECTIVE: The purpose of this study was to compare
the cost-effectiveness of three PPIs for the treatment of
gastric ulcer.
METHODS: We constructed the treatment model for
gastric ulcer treatment, and compared the cost and healed
days of three PPIs, Lansoprazole, Omeprazole and Ra-
beprazole, and Famotidine, a histamine2 blocker. Since
the approved maximum treatment duration was 8 weeks
for PPIs, the time horizon of this study was set to 8
weeks. The healing rates at 2, 4, 6, and 8 weeks were
taken from the independent randomized controlled trials.
In these trials, the comparator was Famotidine and the
endpoint was endoscopically confirmed healing. The fee
schedule set by the Japanese Ministry of Health and Wel-
fare was used for cost calculation.
RESULTS: Incremental costs compared to Famotidine
were -3,936 yen for Lansoprazole, +1,240 yen for
Omeprazole, and -6,037 yen for Rabeprazole. Incre-
mental healed days compared to Famotidine were 8.9,
3.7, and 11.3 days, respectively. Therefore, the treatment
by Rabeprazole was the least expensive and the most ef-
fective among the three PPIs.
CONCLUSION: Among the PPIs available in Japan, Ra-
beprazole was considered to be the most cost-effective
treatment option for gastric ulcer.
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OBJECTIVE: To prospectively assess direct medical costs
incurred by primary cadaveric renal transplant patients
during the initial six month post-transplant period.
METHODS: A subset of patients enrolled in a phase IIIb
renal transplant clinical trial comparing two formulations
of cyclosporine A participated in a prospective economic
evaluation that included the collection of hospital bills
and monthly patient telephone surveys. Direct medical
costs were determined for all hospitalizations, outpatient
provider visits, and urgent care center visits. Both the
UB-92 and itemized hospital bills were requested for all
reported hospitalizations. For outpatient encounters, the
length and reason for visit were used to assign an appro-
priate Current Procedural Terminology code with the
corresponding reimbursement determined using the 1996
Abstracts
Medicare Resource Based Relative Value Scale payment
system. Analyses were performed from the perspective of
Medicare, the primary payer of medical care for end-
stage renal disease patients in the U.S.
RESULTS: 69 of the 119 patients participating in the
economic evaluation had complete data and were in-
cluded in the analyses. The mean cost per patient (± SD)
for the transplant hospitalization was $51,997 (± $16,854).
Mean per patient costs for hospitalizations that occurred
during the follow-up period were $5,687 (± $12,906).
Mean outpatient costs were $423 (± $445).
CONCLUSION: Total direct medical costs per patient
for the first six months post transplant were $58,171
(± $20,539). Limitations of this study included the in-
ability to collect all hospital bills, the exclusion of inpa-
tient professional fees, and reliance on patient recall.
Clinical data will be used to supplement the telephone
survey results and to differentiate between transplant and
non-transplant related hospitalizations.
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